<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2479">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04346199</url>
  </required_header>
  <id_info>
    <org_study_id>D822FC00001</org_study_id>
    <nct_id>NCT04346199</nct_id>
  </id_info>
  <brief_title>Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.</brief_title>
  <acronym>CALAVI</acronym>
  <official_title>A Phase 2, Open Label, Randomized Study of the Efficacy and Safety of Acalabrutinib With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Acerta Pharma B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      CALAVI will investigate the safety, efficacy and pharmacokinetics of acalabrutinib together&#xD;
      with Best Supportive Care in the treatment of COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 12, 2020</start_date>
  <completion_date type="Actual">November 17, 2020</completion_date>
  <primary_completion_date type="Actual">November 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Study will consist of two arms Arm 1 is acalabrutinib + best supportive care or Arm 2 is best supportive care alone</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Subject alive and free of respiratory failure</measure>
    <time_frame>Day 14</time_frame>
    <description>Respiratory failure, is defined based on resource utilization of any of the following modalities:&#xD;
Endotracheal intubation and mechanical ventilation&#xD;
Oxygen delivered by high-flow nasal cannula (heated, humidified, oxygen delivered via reinforced nasal cannula at flow rates &gt;20 L/min with fraction of delivered oxygen ≥0.5)&#xD;
Noninvasive positive pressure ventilation or continuous positive airway pressure&#xD;
Extracorporeal membrane oxygenation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects alive and free of respiratory failure</measure>
    <time_frame>Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline in CRP</measure>
    <time_frame>Days 3, 5, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in ferritin</measure>
    <time_frame>Days 3, 5, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chnage from baseline in absolute lymphocyte counts</measure>
    <time_frame>Days 3, 5, 7, 10, 14, 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects alive and discharged from ICU</measure>
    <time_frame>Days 14 and 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from randomization to first occurrence of respiratory failure or death on study due to any cause</measure>
    <time_frame>Up to 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive and free of respiratory failure</measure>
    <time_frame>To 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days with respiratory failure</measure>
    <time_frame>to 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days hospitalized</measure>
    <time_frame>To 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in ICU (length of stay)</measure>
    <time_frame>To 90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive outside of hospital</measure>
    <time_frame>To 28 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days alive outside of hospital</measure>
    <time_frame>To 90 days after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in oxygenation index (PaO2/FiO2)</measure>
    <time_frame>To Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events and Serious Adverse Events</measure>
    <time_frame>28 days after last dose</time_frame>
    <description>Type, frequency, severity, and relationship to study treatment of any TEAEs or abnormalities of laboratory tests, SAEs, or AEs leading to discontinuation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Cmax)</measure>
    <time_frame>28 days after last dose</time_frame>
    <description>Peak Plasma Concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (Tmax)</measure>
    <time_frame>28 days after last dose</time_frame>
    <description>Time to Maximum Concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of acalabrutinib and its active metabolite ACP- 5862 (AUC)</measure>
    <time_frame>28 days after last dose</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">177</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Acalabrutinib+ Best Supportive Care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best Supportive Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acalabrutinib</intervention_name>
    <description>Acalabrutinib- administered orally</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent or have a legal representative provide consent and authorization to&#xD;
             use protected health information (in accordance with national and local patient&#xD;
             privacy regulations)&#xD;
&#xD;
          2. Men and women ≥18 years of age at the time of signing the informed consent form&#xD;
&#xD;
          3. Confirmed infection with SARS-CoV-2 confirmed per World Health Organization (WHO)&#xD;
             criteria (including positive RT-PCR nucleic acid test of any specimen [eg,&#xD;
             respiratory, blood, urine, stool, or other bodily fluid]) within 4 days of&#xD;
             randomization&#xD;
&#xD;
          4. COVID-19 pneumonia (documented radiographically) requiring hospitalization and oxygen&#xD;
             saturation &lt;94% on room air or requires supplemental oxygen&#xD;
&#xD;
          5. Able to swallow pills&#xD;
&#xD;
          6. Willing to follow contraception guidelines&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Respiratory failure at time of screening due to COVID-19&#xD;
&#xD;
          2. Known medical resuscitation within 14 days of randomization&#xD;
&#xD;
          3. Pregnant or breast feeding&#xD;
&#xD;
          4. Suspected uncontrolled active bacterial, fungal, viral, or other infection (besides&#xD;
             infection with SARS-CoV-2)&#xD;
&#xD;
          5. Alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin ≥ 3x&#xD;
             upper limit of normal (ULN) and/or severe hepatic impairment detected within 24 hours&#xD;
             at screening (per local lab)&#xD;
&#xD;
          6. Uncontrolled or untreated symptomatic arrhythmias, myocardial infarction within the&#xD;
             last 6 weeks, or congestive heart failure (NYHA Grade 3 or 4). Exception: Subjects&#xD;
             with controlled, asymptomatic atrial fibrillation during screening are allowed to&#xD;
             enroll&#xD;
&#xD;
          7. Treatment with a strong cytochrome P450 (CYP)3A inhibitor (within 14 days before first&#xD;
             dose of study drug) or inducer (within 7 days before first dose of study drug).&#xD;
&#xD;
          8. Requires treatment with proton-pump inhibitors (PPIs; eg, omeprazole, esomeprazole,&#xD;
             lansoprazole, dexlansoprazole, rabeprazole, or pantoprazole). Subjects receiving PPIs&#xD;
             who switch to H2-receptor antagonists or antacids are eligible for enrollment in this&#xD;
             study&#xD;
&#xD;
          9. Received oral antirejection or immunomodulatory drugs (eg, anticytokines, Btk&#xD;
             inhibitors, JAK inhibitors, PI3K inhibitors) within 30 days before randomization on&#xD;
             study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>130 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>1221</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ciudad de Buenos Aires</city>
        <zip>C1180AAX</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monte Grande</city>
        <zip>B1842</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramos Mejía</city>
        <zip>B1704</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Botucatu</city>
        <zip>18618-687</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Florianópolis</city>
        <zip>88036-800</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <zip>91350-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ribeirão Preto</city>
        <zip>14051-140</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salvador</city>
        <zip>40110-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Bernardo do Campo</city>
        <zip>09715090</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>01327-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04004-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Curico</city>
        <zip>3341643</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago</city>
        <zip>7500692</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Talca</city>
        <zip>3460001</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gauting</city>
        <zip>82131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bangalore</city>
        <zip>560002</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Delhi</city>
        <zip>110017</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <zip>162-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>D.F</city>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Monterrey</city>
        <zip>64461</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>México</city>
        <zip>03103</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>15324</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 11</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lima</city>
        <zip>LIMA 1</zip>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123182</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>143442</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murmansk</city>
        <zip>183047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>George</city>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>1827</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <zip>06800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bakirkoy</city>
        <zip>34147</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <zip>34214</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Umraniye</city>
        <zip>34760</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>France</country>
    <country>Germany</country>
    <country>India</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Turkey</country>
  </location_countries>
  <removed_countries>
    <country>Spain</country>
  </removed_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 9, 2020</study_first_submitted>
  <study_first_submitted_qc>April 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2020</study_first_posted>
  <last_update_submitted>February 1, 2021</last_update_submitted>
  <last_update_submitted_qc>February 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>2019 novel coronavirus disease</keyword>
  <keyword>Acalabrutinib</keyword>
  <keyword>Btk inhibitor</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

